Maharashtra: Free treatment for Covid-19 and other ailments now till October 31

PUNE: The state extended the time period for citizens to avail free treatment for a host of ailments including Covid-19 under the Mahatma Jyotiba Phule Jan Arogya Yojana (MJPJY) till October 31. Every Maharashtra resident is eligible for this benefit, irrespective of financial status. On May 23, the state had initially allowed citizens to avail the free treatments till July 31. Health activists had urged the state to extend the scheme, as many suffered financial setbacks due to the pandemic. The losses, activists said, necessitated the need for free treatment for all kinds of ailments, including Covid-19, for at least a year. ....read more

Current Issues in COVID-19

Community response, vaccines, and new COVID tests. Know more about them and several other issues clouding COVID 19 today. Join MEDtalks with Dr K K Aggarwal at 7:00 PM today for a discussion on New Issues in COVID-19.Just click on www.facebook.com/drkkaggarwal or https://perfecthealthmela.com/vevent/general-webinar.php

Maharashtra: Free treatment for Covid-19 and other ailments now till October 31

PUNE: The state extended the time period for citizens to avail free treatment for a host of ailments including Covid-19 under the Mahatma Jyotiba Phule Jan Arogya Yojana (MJPJY) till October 31. Every Maharashtra resident is eligible for this benefit, irrespective of financial status. On May 23, the state had initially allowed citizens to avail the free treatments till July 31. Health activists had urged the state to extend the scheme, as many suffered financial setbacks due to the pandemic. The losses, activists said, necessitated the need for free treatment for all kinds of ailments, including Covid-19, for at least a year. ....read more

Current Issues in COVID-19

Community response, vaccines, and new COVID tests. Know more about them and several other issues clouding COVID 19 today. Join MEDtalks with Dr K K Aggarwal at 7:00 PM today for a discussion on New Issues in COVID-19.Just click on www.facebook.com/drkkaggarwal or https://perfecthealthmela.com/vevent/general-webinar.php

Healthcare News Monitor

Pharma, med device manufacturers allowed to invest ‘philanthropic doles’ in Covid research

The pioneer

To boost research and activities for vaccine development to combat Covid-19, the Government has expanded the ambit of the Corporate Social Responsibility (CSR) umbrella, allowing the pharma and medical device manufacturers to invest the ‘philanthropic doles’ in researches related to the pandemic for the next three years. The Government has amended the Companies (Corporate Social Responsibility Policy) Rules, 2014 in this regard. A senior official from the Union Ministry of Corporate Affairs said that a provision in Companies (Corporate Social Responsibility Policy) Rules, 2014 has been “inserted through amendment that would allow pharmaceutical, vaccine and medical device firms engaged in R&D activities of new vaccine, drugs and medical devices in their normal course of business to claim CSR benefits for undertaking R&D activity of new vaccine, drugs and medical devices related to the virus.” The provision will be available for fiscal years 2020-21, 2021-22 and 2022-23.

Demand for online doctors creates $39 billion titan in Japan

Livemint

Two decades ago, Itaru Tanimura ended a 12-year run at McKinsey & Co. to lead M3 Inc., an online provider of medical information and services backed by entertainment giant Sony Corp. What followed was a flurry of acquisitions that turned the Tokyo-based company into a $39 billion global behemoth. M3 now has about 40 subsidiaries and affiliates, including MDLinx Inc. in the U.S. and Britain’s Doctors.net.uk Ltd. M3 helps pharmaceutical companies, doctors and their patients access information online over its platforms, removing the need for in-person visits -- something that proved important in the time of Covid-19. Its shares have almost doubled this year, surging the most of any company in the Nikkei 225 Stock Average and taking the fortune of Tanimura to $1.2 billion, according to the Bloomberg Billionaires Index.

Dr Padmavati, among India’s top cardiologists, dies at 103

The Indian Express

A strong-willed woman, a pioneer in cardiology and a doctor with a heart of gold – this is how the medical fraternity remembers 103-year-old cardiologist Dr Padmavati Sivaramakrishna Iyer, known simply as Dr Padmavati, who passed away Saturday after contracting Covid-19 earlier this month. She was admitted to the National Heart Institute (NHI) 11 days ago and later developed pneumonia. She was put on ventilator support but suffered a cardiac arrest on Saturday. The founding director of NHI, she was awarded the Padma Bhushan in 1967 and the Padma Vibhushan in 1992. She was also the recipient of Harvard Medical International Award, Dr BC Roy Award and Kamla Menon Research Award.